Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 23,240 Shares of Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 23,240 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $5.00, for a total transaction of $116,200.00. Following the transaction, the chief executive officer now directly owns 15,177,512 shares of the company’s stock, valued at approximately $75,887,560. This trade represents a 0.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Zaccardelli also recently made the following trade(s):

• On Monday, December 2nd, David Zaccardelli sold 3,200 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $16,000.00.
• On Friday, November 29th, David Zaccardelli sold 98,888 shares of Verona Pharma stock. The shares were sold at an average price of $5.01, for a total value of $495,428.88.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total value of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The shares were sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Price Performance

Verona Pharma stock opened at $39.11 on Tuesday. The firm has a fifty day moving average of $34.85 and a 200-day moving average of $25.61. Verona Pharma plc has a 52-week low of $11.39 and a 52-week high of $40.76. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $3.13 billion, a P/E ratio of -20.37 and a beta of 0.46.

Verona Pharma (NASDAQ:VRNA) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The company had revenue of $5.62 million during the quarter, compared to analysts’ expectations of $2.31 million. During the same period in the prior year, the company posted ($0.18) EPS. As a group, analysts predict that Verona Pharma plc will post -2.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VRNA. HC Wainwright upped their price objective on shares of Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group increased their price target on shares of Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Truist Financial boosted their price objective on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company increased their target price on Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verona Pharma has a consensus rating of “Buy” and a consensus target price of $43.83.

Institutional Investors Weigh In On Verona Pharma

Several hedge funds have recently modified their holdings of VRNA. CWM LLC acquired a new stake in Verona Pharma in the second quarter valued at approximately $29,000. EMC Capital Management acquired a new stake in Verona Pharma during the 2nd quarter valued at $38,000. GAMMA Investing LLC increased its stake in Verona Pharma by 70.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock worth $38,000 after buying an additional 553 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Verona Pharma by 25.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after buying an additional 529 shares in the last quarter. Finally, Legato Capital Management LLC purchased a new position in Verona Pharma in the 2nd quarter valued at about $154,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.